Advisory Committee Review Will Test Whether One Trial Will Do The Trick For Bristol's Ipilimumab
This article was originally published in The Pink Sheet Daily
Executive Summary
Panelists may want to wait for results from a second Phase III trial and, given severe side effects, are likely to want a robust risk management plan.